SCHEMBL419469

SCHEMBL419469

O=C(Nc1cccc(F)c1)N1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.68
KMT2A Q03164 2/20 0.67
ALDH1A1 P00352 6/20 0.66
MEN1 O00255 1/20 0.66
RECQL P46063 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
CYP2D6 P10635 3/20 0.65
NPC1 O15118 2/20 0.65
USP2 O75604 2/20 0.64
CYP2C19 P33261 2/20 0.64
MAPT P10636 1/20 0.63
CYP3A4 P08684 2/20 0.62
CYP1A2 P05177 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
TSHR P16473 1/20 0.62
CA12 O43570 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
CA9 Q16790 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22218771 0.86 NPC1 (0.67) KMT2AALDH1A1MEN1CYP2D6NPC1
SCHEMBL1575063 0.85 TP53 (0.58) RAB9AALDH1A1CYP2D6NPC1USP2
SCHEMBL1575354 0.85 TP53 (0.58) RAB9AALDH1A1CYP2D6NPC1USP2
SCHEMBL3552835 0.85 ALDH1A1 (0.62) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL20236578 0.85 ALDH1A1 (0.62) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL2403385 0.85 ALDH1A1 (0.76) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL4311734 0.85 KDM4E (0.68) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL20237020 0.85 SMN1; SMN2 (0.68) RAB9AKMT2AALDH1A1MEN1NPSR1
SCHEMBL22217924 0.84 ALDH1A1 (0.61) ALDH1A1CYP2D6NPC1USP2CYP2C19
SCHEMBL1574692 0.83 TP53 (0.59) ALDH1A1CYP2D6NPC1USP2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114524780-A Mercaptobenzothiazole urea compound, pharmaceutical preparation, preparation method and application 绍兴市上虞区武汉理工大学高等研究院 2022-05-24 CN disclosed
US-8106048-B2 protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester 4SC AG (DE) 2012-01-31 US disclosed
US-20120022068-A1 NOVEL HETEROCYCLIC NF-kB INHIBITORS 4SC AG (DE) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022068-A1 NOVEL HETEROCYCLIC NF-kB INHIBITORS NFKB2, NFKBIA, NFRKB RAB9A 3958/4885KMT2A 645/4885ALDH1A1 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.